Imipenem/cilastatin/relebactam (Recarbrio®) is indicated for the treatment of infections due to aerobic gram-negative organisms in adults with limited treatment options.
|NCPE Assessment Process||Complete|
|Rapid review commissioned||31/08/2020|
|Rapid review completed||21/10/2020|
|Rapid Review outcome||A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of imipenem/cilastatin/relebactam compared with the current standard of care, on the basis of the proposed price relative to currently available therapies.|